Small molecule · Inhibitor of PRMT5 · developed by Tango Therapeutics
Vopimetostat (TNG462) is an orally bioavailable small molecule that selectively binds and inhibits PRMT5, a methyltransferase that adds methyl groups to histone and other protein arginine residues. It is designed to be especially active in MTAP-deleted cancer cells, and is being studied in solid tumors including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07897734 | Phase 1/2 | PDAC | Not yet recruiting | TNGX |
| NCT06922591 | Phase 1/2 | PDAC | Recruiting | RVMD |
| NCT05732831 | Phase 1/2 | Locally Advanced Solid Tumor | Recruiting | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally Advanced Solid TumorLung CancerMTAP DeletionNSCLCPancreatic Cancer MetastaticPDACPDAC - Pancreatic Ductal AdenocarcinomaRAS MutationThoracic Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.
See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNGX catalysts and pipeline →